Bio Sequence

Biological Glossary | What are Complementarity-determining regions (CDRs)?

27 October 2023
2 min read

Complementarity-determining regions (CDRs) are essential components of the variable chains found in immunoglobulins (antibodies) and T cell receptors. They are generated by B-cells and T-cells and are responsible for binding to specific antigens. A collection of CDRs makes up a paratope. With their variation, CDRs contribute significantly to the range of antigen specificities produced by lymphocytes.

On the amino acid sequence of an antigen receptor's variable domain, there are three CDRs: CDR1, CDR2, and CDR3. As most antigen receptors consist of two variable domains, each receptor can have up to six CDRs that can interact with the antigen. Hence, a single antibody molecule, containing two antigen receptors, has twelve CDRs in total.

These CDR regions exhibit the most sequence variation associated with immunoglobulins and T cell receptors, earning them the designation of hypervariable regions. Within the variable domain, CDR1 and CDR2 are present in the variable region, while CDR3 encompasses parts of the variable, diversity, and joining regions, with CDR3 being the most variable.

The tertiary structure of an antibody, which often involves the analysis and design of new antibodies, relies heavily on the CDRs. Various computational methods, such as homology modeling and the H3-rules, are used to build models of CDRs, particularly of the CDR3.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

Celltrion's Infliximab (subcutaneous formulation) receives FDA approval for the treatment of inflammatory bowel disease
Latest Hotspot
3 min read
Celltrion's Infliximab (subcutaneous formulation) receives FDA approval for the treatment of inflammatory bowel disease
27 October 2023
On Oct 25, 2023, Celltrion reported US FDA approval of Zymfentra (infliximab) for continued treatment of adult ulcerative colitis (UC) and Crohn's disease (CD) after intravenous infliximab treatment.
Read →
Biological Glossary | What is Attenuator?
Bio Sequence
3 min read
Biological Glossary | What is Attenuator?
27 October 2023
Attenuator in biotechnology refers to a nucleotide sequence in DNA that can lead to premature termination of transcription, a process found in bacteria and archaea.
Read →
Yasheng Pharmaceutical's Bcl-2/Bcl-xL dual-target inhibitor, APG-1252, releases its latest Phase 1b clinical trial data for the treatment of non-small cell lung cancer
Latest Hotspot
3 min read
Yasheng Pharmaceutical's Bcl-2/Bcl-xL dual-target inhibitor, APG-1252, releases its latest Phase 1b clinical trial data for the treatment of non-small cell lung cancer
26 October 2023
Yasheng Pharmaceutical presented updated clinical data for APG-1252 and Osimertinib to treat EGFR mutation lung cancer patients at the 2023 ESMO meeting on October 23, 2023.
Read →
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
Hot Spotlight
7 min read
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
26 October 2023
Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.